Skip to main content

First Patient Receives In Vivo CRISPR Editing

Doctors in Oregon delivered the gene editing machinery behind the retina in hopes of treating an inherited form of blindness, according to the companies that developed the therapy.

Written byJef Akst
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00

ABOVE: © ISTOCK.COM, ARTURSFOTO

Update (November 17, 2022): Only 3 out of 14 patients experienced “clinically meaningful improvements” when treated with the CRISPR-based therapy in a Phase 1/2 trial, Editas announced today. The company added that it is pausing enrollment but is looking for a collaborator to continue development. “We’ve demonstrated that we can safely deliver a CRISPR-based gene editing therapeutic to the retina and have clinically meaningful outcomes,” Editas President and CEO Gilmore O’Neill said in the announcement.

Cambridge, Massachusetts–based Editas Medicine and Dublin-based Allergan announced today (March 4) that doctors at the Casey Eye Institute of Oregon Health & Science University in Portland used CRISPR gene editing inside a patient for the first time. They are attempting to treat an inherited form of blindness called Leber congenital amaurosis, the Associated Press reports. The scientists say they will know within a few weeks if the treatment is working and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi
Advancing Research With Humanized Mouse Models

Advancing Research with Next-Generation Humanized Mouse Models

bioxcell
3d illustration showing amyloid plaques in Alzheimer's disease

Best Practices for Blood-Based Amyloid Pathology Testing

fujirebio logo

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen